EUSOL Biotech (6652) Stock Overview

Eusol Biotech Co.,Ltd. focuses on research and development of new biotech drugs for sleep disorders. Its pipeline includes ES135, a recombinant human acidic fibroblast growth factor (rhFGF1) for repairing neuron function; and SM-1, a 3-in-1 capsule containing 3 commercial drugs with sedative effect. The company was founded in 1994 and is headquartered in Taipei, Taiwan.